VenatoRx has the potential to receive funding of up to USD 7.4m over five years if all project milestones are met.
VenatoRx's collaborators include leading academicians and scientists from Robert Frederick Smith School of Chemical and Bimolecular Engineering at Cornell University; Broad Institute of MIT and Harvard; Gfree Bio, LLC; and Centro de Química-Física Molecular at the University of Lisbon, Portugal.
The objective of this R01 grant is to provide tools that can facilitate therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae, multi-drug resistant Acinetobacter baumannii and/or MDR Pseudomonas aeruginosa.
This initiative will also support VenatoRx's discovery programs targeting novel antibacterial agents.
The project is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI136805.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections.
The company's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor that directly inhibits all four Ambler classes of beta-lactamases, including the emerging carbapenemases KPC and NDM-1.
In addition, VenatoRx has a broad pipeline of preclinical programmes, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer